Anebulo Pharmaceuticals IncNASDAQ:ANEB
- LAST PRICE1.4200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.4000/ 10
- Ask / Lots1.5100/ 3
- Open / Previous Close--- / 1.4200
- Day Range---
- 52 Week Range
- Volume4
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Nov 19, 2024
DJ Anebulo Pharmaceuticals Price Target Maintained With a $8.00/Share by Benchmark, from 8:55AM ET on Tuesday Nov 19, 2024 by Dow Jones
8:55AM ET on Tuesday Nov 19, 2024 by Dow Jones
Nov 13, 2024
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow JonesPress Release: Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates, from 4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:05PM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Anebulo Pharmaceuticals Inc | 36.8M | -4.6x | --- |
ALT5 Sigma Corp | 36.6M | -0.7x | --- |
RAPT Therapeutics Inc | 36.2M | -0.4x | --- |
HST Global Inc | 37.6M | -61.1x | --- |
Forte Biosciences Inc | 35.9M | -1.3x | --- |
Lantern Pharma Inc | 37.7M | -2.1x | --- |
Company Information
Anebulo Pharmaceuticals, Inc. is a clinical-stage biotechnology company. It is engaged in developing treatments for cannabis toxicity, such as unintentional cannabis poisoning, acute cannabinoid intoxication (ACI) and the landscape of acute cannabis-induced conditions. Its lead product candidate is selonabant, a potent, small molecule antagonist of cannabinoid binding receptor type-1 (CB1), the primary receptor involved in the psychotropic effects of cannabinoids, with the potential to address the unmet medical need for a therapy to treat cannabis toxicity. Selonabant is orally bioavailable, rapidly absorbed, and has also been formulated for intravenous treatment. Selonabant has completed dosing in a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of acute cannabinoid intoxication. It is also prioritizing the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with unintentional cannabis poisoning.
Contact Information
- Headquarters
- Jfl Capital Management 1017 Rr 620 S, Suite 107LAKEWAY, TX, United States 78734
- Phone
- 512-598-0931
- Fax
- ---
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $36.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 25.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.10 |
EPS | $-0.31 |
Book Value | $0.15 |
P/E Ratio | -4.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
